EUVIMEDEUVIMED entdecken
Kommentar

Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19

Sahar Ashraf, Nauman Ashraf

JAMA · 2023

DOI: 10.1001/jama.2023.5061 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA, 2023. Verfasst von Sahar Ashraf und 1 weiteren Autor:innen. Beteiligte Einrichtung: Northpointe Psychiatry, Lewisville, Texas. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Fluvoxamine. Die Arbeit nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentFluvoxamineHumansDouble-Blind MethodTime FactorsRecovery of Function

Substanzen

Antiviral AgentsFluvoxamine

Autor:innen und Institutionen

  • Northpointe Psychiatry, Lewisville, Texas.
  • Kansas City University, Ozark Center, Joplin, Missouri.

Zitieren

APA

Ashraf, S., & Ashraf, N. (2023). Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA. https://doi.org/10.1001/jama.2023.5061

Vancouver

Ashraf S, Ashraf N. Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19. JAMA. 2023. doi:10.1001/jama.2023.5061

BibTeX
@article{Ashraf2023,
  author = {Ashraf, Sahar and Ashraf, Nauman},
  title = {Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.5061}
}
Kostenlos starten →